News & Events

Novel AMPLIVANT™ Technology Introduced at AACR Annual Meeting 2013

April 12, 2013
AMPLIVANT™ TLR-ligand adjuvant to improve immunotherapies Leiden, The Netherlands, April 9, 2013 - ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed ther...
Read more

InteRNA Technologies secures additional equity financing to progress lead program for melanoma treatment

March 26, 2013
Utrecht/Amsterdam, The Netherlands, March 26, 2013 - InteRNA Technologies B.V., a biopharma company engaged in the development of microRNA (miRNA)-based therapeutics for oncology, announces today the closing...
Read more

Merus Further Expands R&D Capacity

March 07, 2013
Company Contracts R&D Service Provider FairJourney Biologics Utrecht, The Netherlands, March 7, 2013 - Merus B.V., a biopharmaceutical company focusing on innovative human antibody therapeutics, today annou...
Read more

Merus Achieves Milestone with Novartis Option Fund

February 07, 2013
Company Reaches Milestone in Biclonics™ Program Partnered with Novartis Utrecht, The Netherlands, February 7, 2013 - Merus B.V., a biopharmaceutical company focusing on innovative human antibody therapeutic...
Read more

OcellO and Merus sign agreement for screening bispecific cancer antibodies

January 14, 2013
Leiden and Utrecht, The Netherlands, January 14, 2013 - OcellO B.V. and Merus B.V. have entered into a collaboration under which OcellO will provide screening services to Merus. OcellO will use its 3D cell c...
Read more

ISA Pharmaceuticals Secures EUR 8 Million Funding

January 08, 2013
Leiden, the Netherlands, January 7, 2013 - ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infect...
Read more

Merus Selects Clinical Candidate for the Treatment of Acute Myeloid Leukemia (AML)

January 07, 2013
Utrecht, The Netherlands, January 7, 2013 - Merus B.V., a biopharmaceutical company focusing on innovative human antibody therapeutics, today announced that it has selected MCLA-117 as lead candidate for cli...
Read more

Merus Appoints Setareh van Driel Shamsili as Chief Medical Officer

December 14, 2012
Utrecht, The Netherlands, December 11, 2012 - Merus B.V., a biopharmaceutical company focused on innovative human antibody therapeutics, today announced the appointment of Setareh van Driel Shamsili, MD, Ph....
Read more

SomantiX and VU University Medical Center Amsterdam receive EuroTransBio (ETB) Grant for Tumor Vessel Targeting program

November 08, 2012
Amsterdam, The Netherlands, November 7th 2011 - The grant of EUR 1.5 million is awarded to a multidisciplinary consortium including SomantiX and the VU University Medical Center Amsterdam by the European col...
Read more

InteRNA Technologies receives notice of allowance for miRNA sequences of its lead pre-clinical product

October 15, 2012
Patent covers the precursor and mature sequences of miRNA-3157, the Company's lead product in its B-Raf/melanoma program Nijmegen/Utrecht, the Netherlands - October 15, 2012 - InteRNA Technologies B.V., a d...
Read more

Merus announces the full validation of its MeMo(R) transgenic mouse for common light chain human antibodies

October 09, 2012
UTRECHT - The Netherlands - October 8, 2012 - Merus B.V., a biopharmaceutical company focused on innovative human antibody therapeutics, announced today the full validation of its transgenic MeMo® mouse for...
Read more

ORCA Therapeutics strengthens its Patent Portfolio

September 06, 2012
Amsterdam, The Netherlands - September 6th, 2012 - ORCA Therapeutics BV, a pioneer in the development of innovative virotherapies for treatment of cancer, announced today that it has expanded its patent port...
Read more

Merus receives EP patent covering the expression of defined antibody combinations

June 21, 2012
Utrecht, The Netherlands, June 20, 2012 - Merus B.V., a biopharmaceutical company focused on multispecific human antibody therapeutics, announced today that it has been granted the first European patent cove...
Read more

Merus announces appointment of Jason Avery as Chief Business Officer

June 18, 2012
Utrecht, The Netherlands, June 15, 2012 - Merus B.V., a biopharmaceutical company focused on multispecific human antibody therapeutics, announced today that Jason Avery has been appointed as Chief Business O...
Read more

InteRNA Technologies announces establishment of Supervisory Board

November 21, 2011
Nijmegen/Utrecht (the Netherlands) - November 21, 2011 - InteRNA Technologies B.V., a drug discovery and development company engaged in the development of microRNA-based therapeutics for oncology, announces...
Read more

ORCA Therapeutics receives up to € 5 Million Innovation Credit from Dutch Government

November 08, 2011
Amsterdam, The Netherlands - November 8th, 2011 - ORCA Therapeutics BV, a pioneer in the development of innovative virotherapies for treatment of cancer, announces today that it has received an innovation cr...
Read more

InteRNA Technologies and Dana-Farber Cancer Institute to collaborate on the role of microRNAs in cancer pathways

November 02, 2011
Utrecht (the Netherlands) - InteRNA Technologies B.V. and the Dana-Farber Cancer Institute (Boston, USA) have entered into a research agreement to develop microRNA (miRNA)-based therapeutics for cancer. Und...
Read more

ISA Pharmaceuticals strengthens its Supervisory Board with the appointment of Professor Jan van de Winkel

October 17, 2011
Leiden, The Netherlands, October 17th, 2011 - ISA Pharmaceuticals, a leader in the development of novel immunotherapeutic products for oncology and infectious diseases, today announced that Professor Jan van...
Read more

FDA grants ISA Pharmaceuticals Orphan Drug Designation for the treatment of Vulvar Intraepithelial Neoplasia with its lead product ISA-HPV-SLP®

October 05, 2011
Leiden, The Netherlands, October 5th , 2011 ISA Pharmaceuticals BV, a leader in the development of immunotherapeutic products for oncology and infectious diseases, today announced that orphan drug designati...
Read more

Merus launches MeMo™, a transgenic mouse for improved therapeutic human monoclonal antibodies

September 27, 2011
Utrecht, The Netherlands, September 27, 2011 - Merus announced today that it has completed the construction of a single-light chain transgenic mouse for the generation of therapeutic human monoclonal antibod...
Read more

Home > News & Events > Archive

© 2019 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds